Navigation Links
FDA Approves Electronic Common Technical Document (eCTD) for Laureate's Regulatory Submissions

PRINCETON, N.J., Sept. 8, 2011 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc. announced today that their Regulatory Services Group (RSG) has been approved by the Food and Drug Administration (FDA) to submit electronic common technical document (eCTD) regulatory submissions to the Agency. The 4 gigabyte test submission comprising CMC, preclinical and clinical data was reviewed, validated and approved without errors and in record time. The endorsement complements Laureate's recent approval to use FDA's electronic submission gateway (ESG).

"This is a major milestone towards completing Laureate's strategy of offering clients submission-ready chemistry, manufacturing and control (CMC) reports, as well as providing a complete regulatory submission service," commented Robert Burford Ph.D. Vice President Regulatory Services. "Clients will now be able to have their regulatory submission services provided by Laureate independent of having clinical supplies manufactured by us."

Laureate's CEO, Michael A. Griffith, commented, "Approval to submit eCTDs to the FDA along with the recently announced approval to use FDA's electronic submission gateway offers Laureate customers a combined service, unique to the industry."  He continued, "By providing clients with a bulk drug substance (BDS) and/or drug product along with submission-ready CMC documentation and the capability to manage the actual submission process is part of Laureate's philosophy of providing clients with a superior contract manufacturing experience."

About Laureate Regulatory Services Group (RSG)

Laureate Regulatory Services Group publishes, submits and manages electronic IND, NDA and BLA submissions as a client service. Specializing in CMC documentation from Upstream, Downstream and Analytical functions performed for clients requiring BDS these reports are created in eCTD format.  Besides publishing and submission services, the RSG also offers a wide range of regulatory support activities including high level consulting re: regulatory strategy, IND completion, report generation and regulatory submission reviews. For more information, contact: Robert Burford, Ph.D., VP Regulatory Services Group, Laureate Biopharmaceutical Services Inc., at (609) 919-3332, or email, or visit

About Laureate Biopharmaceutical Services, Inc.

Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharma, at (609) 919-3367, or or visit

SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
2. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
3. FDA Approves New Device to Treat Brain Aneurysms
4. European Commission Approves DuPont Tender Offer to Acquire Danisco
5. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
6. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
7. FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
8. European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & Processing
9. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
10. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
11. FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... that focuses on a daily routine for managing the ... their medication can affect the way the body absorbs ... to their a daily routine are important. The goal ... help patients better manage their hypothyroidism by establishing a ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult stem ... subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional ... Office of the Chief Scientist (OCS). This grant, the second ... for 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
Breaking Biology News(10 mins):